EP05.01-030 CRISP: First Real-World Evidence of NSCLC Stage I, II and III in Germany - AIO-TRK-0315

Abstract

CRISP (Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients) is a non-interventional, prospective, multi-center clinical research platform whose aim is to understand current treatment reality of patients with lung cancer in Germany. Here we present data of patients diagnosed with early-stage NSCLC (IIIB/C only if treated with curative intent), including first outcome data in routine-care.